Lineage Inc (LINE) concluded trading on Wednesday at a closing price of $48.23, with 4.28 million shares of worth about $206.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -36.74% during that period and on April 30, 2025 the price saw a loss of about -14.62%. Currently the company’s common shares owned by public are about 228.19M shares, out of which, 68.77M shares are available for trading.
Stock saw a price change of -14.70% in past 5 days and over the past one month there was a price change of -17.74%. Over the period of past 52 weeks, stock dropped to lowest price of $46.63 but also hit the highest price of $89.85 during that period. The average intraday trading volume for Lineage Inc shares is 1.01 million. The stock is currently trading -11.47% below its 20-day simple moving average (SMA20), while that difference is down -15.34% for SMA50 and it goes to -28.37% lower than SMA200.
Lineage Inc (NASDAQ: LINE) currently have 228.19M outstanding shares and institutions hold larger chunk of about 32.27% of that.
The stock has a current market capitalization of $11.01B. It has posted earnings per share of -$3.08 in the same period. It has Quick Ratio of 0.74 while making debt-to-equity ratio of 0.81. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LINE, volatility over the week remained 5.36% while standing at 5.50% over the month.
Stock’s fiscal year EPS is expected to rise by 97.58% while it is estimated to increase by 419.92% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on April 10, 2025 offering a Sector perform rating for the stock and assigned a target price of $56 to it. Coverage by Citigroup stated Lineage Inc (LINE) stock as a Neutral in their note to investors on March 28, 2025, suggesting a price target of $64 for the stock. On January 14, 2025, Exane BNP Paribas Initiated their recommendations, while on December 20, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $75. Stock get an Overweight rating from CapitalOne on September 18, 2024.
